Thomas Meyer

9.8k total citations
106 papers, 3.2k citations indexed

About

Thomas Meyer is a scholar working on Neurology, Genetics and Molecular Biology. According to data from OpenAlex, Thomas Meyer has authored 106 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Neurology, 39 papers in Genetics and 26 papers in Molecular Biology. Recurrent topics in Thomas Meyer's work include Amyotrophic Lateral Sclerosis Research (68 papers), Neurogenetic and Muscular Disorders Research (39 papers) and Parkinson's Disease Mechanisms and Treatments (21 papers). Thomas Meyer is often cited by papers focused on Amyotrophic Lateral Sclerosis Research (68 papers), Neurogenetic and Muscular Disorders Research (39 papers) and Parkinson's Disease Mechanisms and Treatments (21 papers). Thomas Meyer collaborates with scholars based in Germany, United States and Switzerland. Thomas Meyer's co-authors include Albert C. Ludolph, Christoph Münch, Hans Peter Wiesmann, Ulrich Meyer, Reinhard Sedlmeier, C. Oliver Hanemann, André Maier, Gabriele Stumm, Johannes Prudlo and Matthias W. Riepe and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Thomas Meyer

99 papers receiving 3.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Meyer Germany 34 1.8k 1.0k 935 744 429 106 3.2k
Terry Heiman‐Patterson United States 35 1.9k 1.1× 1.1k 1.1× 952 1.0× 825 1.1× 474 1.1× 95 3.5k
Helenius J. Schelhaas Netherlands 41 2.8k 1.6× 1.4k 1.4× 1.2k 1.3× 986 1.3× 744 1.7× 97 4.6k
Richard W. Orrell United Kingdom 36 2.2k 1.2× 1.2k 1.1× 1.7k 1.8× 700 0.9× 609 1.4× 90 4.1k
Kathrin Meyer United States 26 1.3k 0.7× 1.2k 1.2× 1.7k 1.8× 468 0.6× 443 1.0× 87 3.5k
Jae‐Kyu Roh South Korea 43 1.9k 1.0× 466 0.4× 1.6k 1.7× 887 1.2× 729 1.7× 120 5.8k
Andrea Malaspina United Kingdom 38 3.0k 1.6× 1.4k 1.4× 1.6k 1.7× 718 1.0× 740 1.7× 104 4.7k
Letizia Mazzini Italy 36 4.0k 2.2× 2.6k 2.5× 1.3k 1.4× 724 1.0× 790 1.8× 134 5.4k
Michael A. van Es Netherlands 30 2.7k 1.5× 1.5k 1.4× 1.0k 1.1× 443 0.6× 643 1.5× 83 3.6k
Anneke J. van der Kooi Netherlands 45 2.0k 1.1× 1.3k 1.2× 3.2k 3.4× 929 1.2× 431 1.0× 151 6.4k
Liying Cui China 30 2.0k 1.1× 723 0.7× 549 0.6× 447 0.6× 593 1.4× 226 3.5k

Countries citing papers authored by Thomas Meyer

Since Specialization
Citations

This map shows the geographic impact of Thomas Meyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Meyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Meyer more than expected).

Fields of papers citing papers by Thomas Meyer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Meyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Meyer. The network helps show where Thomas Meyer may publish in the future.

Co-authorship network of co-authors of Thomas Meyer

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Meyer. A scholar is included among the top collaborators of Thomas Meyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Meyer. Thomas Meyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brinkmann, Volker, et al.. (2025). SOD1 controls neutrophil oxidative burst and microbial killing. The Journal of Immunology. 214(8). 2015–2028. 1 indexed citations
2.
Bernsen, Sarah, et al.. (2025). Serum Cardiac Troponin T Levels as a Therapy Response Marker in Tofersen‐Treated ALS. Muscle & Nerve. 72(3). 509–514. 2 indexed citations
3.
4.
Weishaupt, Jochen H., Peter Körtvélyessy, Ute Weyen, et al.. (2024). Tofersen decreases neurofilament levels supporting the pathogenesis of the SOD1 p.D91A variant in amyotrophic lateral sclerosis patients. SHILAP Revista de lepidopterología. 4(1). 150–150. 11 indexed citations
5.
Ackeifi, Courtney, Randy L. Anderson, Roy W. Beck, et al.. (2024). TNF-α inhibitors for type 1 diabetes: exploring the path to a pivotal clinical trial. Frontiers in Immunology. 15. 1470677–1470677. 10 indexed citations
6.
Meyer, Thomas, Patrick Weydt, Susanne Petri, et al.. (2023). Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in SOD1‐related ALS: Treatment experience in clinical practice. Muscle & Nerve. 67(6). 515–521. 53 indexed citations
7.
Beauchamp, Jennifer E. S., Mengxi Wang, Caroline Cox, et al.. (2023). Feasibility and user-experience of a virtual environment for social connection and education after stroke: A pilot study. Journal of Stroke and Cerebrovascular Diseases. 33(2). 107515–107515. 3 indexed citations
8.
Boentert, Matthias, Dávid Brenner, Torsten Grehl, et al.. (2022). Amyotrophe Lateralsklerose und andere Motoneuronerkrankungen.
9.
Meyer, Thomas, Andreas Funke, Christoph Münch, et al.. (2019). Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD). BMC Neurology. 19(1). 222–222. 39 indexed citations
10.
Vercruysse, Pauline, Jérôme Sinniger, Hajer El Oussini, et al.. (2016). Alterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosis. Brain. 139(4). 1106–1122. 69 indexed citations
11.
Dupuis, Luc, Reinhard Dengler, Michael T. Heneka, et al.. (2012). A Randomized, Double Blind, Placebo-Controlled Trial of Pioglitazone in Combination with Riluzole in Amyotrophic Lateral Sclerosis. PLoS ONE. 7(6). e37885–e37885. 112 indexed citations
12.
Lange, Leslie A., Caroline Ingre, Markus Weber, et al.. (2011). Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Human Molecular Genetics. 20(9). 1697–1700. 113 indexed citations
13.
Meyer, Thomas, et al.. (2008). Thalidomide causes sinus bradycardia in ALS. Journal of Neurology. 255(4). 587–591. 26 indexed citations
14.
Meyer, Thomas, et al.. (2007). Progressive Muskelatrophie. Der Nervenarzt. 78(12). 1383–1388. 3 indexed citations
15.
Svenson, James E. & Thomas Meyer. (2007). Effectiveness of nonnarcotic protocol for the treatment of acute exacerbations of chronic nonmalignant pain. The American Journal of Emergency Medicine. 25(4). 445–449. 22 indexed citations
16.
Münch, Christoph, Roman Meyer, Thomas Meyer, et al.. (2007). The p150 subunit of dynactin (DCTN1) gene in multiple sclerosis. Acta Neurologica Scandinavica. 116(4). 231–234. 4 indexed citations
17.
Gilling, Mette, Stefan Gesk, Reiner Siebert, et al.. (2006). Breakpoint Cloning and Haplotype Analysis Indicate a Single Origin of the Common Inv(10)(p11.2q21.2) Mutation among Northern Europeans. The American Journal of Human Genetics. 78(5). 878–883. 30 indexed citations
18.
Gottschalk, Nina, Robert A.J. Oostendorp, C. Peschel, et al.. (2005). Das STEMMAT-Projekt als Teil der Gesundheitsinitiative BayernAktiv: Adulte Stammzellen aus Nabelschnur und -blut als Alternative zur embryonalen Stammzellforschung. Zentralblatt für Gynäkologie. 127(6). 368–372. 4 indexed citations
19.
Münch, Christoph, Benzhong Zhu, Stefan Stamm, et al.. (2002). Alternative splicing of the 5′‐sequences of the mouse EAAT2 glutamate transporter and expression in a transgenic model for amyotrophic lateral sclerosis. Journal of Neurochemistry. 82(3). 594–603. 36 indexed citations
20.
Meyer, Thomas, et al.. (1997). Type-4 pili: biogenesis, adhesins, protein export and DNA import. Adelaide Research & Scholarship (AR&S) (University of Adelaide). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Terry Heiman‐Patterson Breakdown of academic impact, for papers by Helenius J. Schelhaas Breakdown of academic impact, for papers by Richard W. Orrell Breakdown of academic impact, for papers by Kathrin Meyer Breakdown of academic impact, for papers by Jae‐Kyu Roh Breakdown of academic impact, for papers by Andrea Malaspina Breakdown of academic impact, for papers by Letizia Mazzini Breakdown of academic impact, for papers by Michael A. van Es Breakdown of academic impact, for papers by Anneke J. van der Kooi Breakdown of academic impact, for papers by Liying Cui
Rankless by CCL
2026